OncoTargets and Therapy · 2016 · 28 citations · 25 references
MedicineOncologySurgeryGastrointestinal OncologySurgical OncologySurvival AnalysisCancer BiomarkersCancer Survival AnalysisPreoperative Oncology AssessmentPrognostic AssessmentSurvival OutcomesAlbumin QuantificationBiomarkers Of Gastric CancerNeutrophil-to-lymphocyte RatioPrognostic Marker EvaluationRisk Stratification Scores
BACKGROUND: In patients with gastric cancer (GC), survival is poor, given the late diagnosis. Risk-stratifying these patients earlier could help improve care. We determined whether combining preoperative albumin concentration and the neutrophil lymphocyte ratio (COA-NLR) could predict overall survival (OS) better than other prognostic indexes. METHODS: We calculated the COA-NLR and other prognostic indexes with data obtained within 1 week before surgery in a retrospective analysis of patients with GC undergoing curative resection between September 2000 and November 2012. Patients with concentrations of hypoalbuminemia above 35 g/L and an NLR value of 2.3 or higher were given a score of 2. Patients with one of these conditions or neither were allocated scores of 1 or 0, respectively. Patients were monitored until July 2014. RESULTS: OS in the 873 eligible patients was 44.9% in patients with a COA-NLR score of 0, 29.8% in patients with a score of 1, and 20.3% in patients with a score of 2 (P<0.001). The COA-NLR score was independently associated with OS (hazard ratio, 1.35; 95% confidence interval, 1.12 to 1.63; P=0.002). Moreover, the area under the receiver operating characteristics curve was 0.62 for the COA-NLR, which was significantly higher (<0.001) than that of the NLR ratio (0.60), the Glasgow prognostic score (0.58), and the platelet lymphocyte ratio (0.54). The COA-NLR was especially accurate for patients with stage I-II GC and the three values (0, 1, and 2) divided patients into subgroups more accurately than did the other indexes (area under the curve value: 0.66, P<0.001). CONCLUSION: The preoperative COA-NLR index is useful for predicting postoperative OS in patients with GC and can be used to guide targeted therapy.
25
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global Cancer Statistics, 2002
Donald Maxwell Parkin, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2005 · 18.4K citations · Full text
Donald Maxwell Parkin, Paola Pisani, Jacques Ferlay · CA A Cancer Journal for Clinicians · 1999 · 3.4K citations · Full text
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine · 2007 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +11